Zyto Group is a holding created from the acquisition of three companies: Zytomed Systems GmbH, ZytoVision GmbH and 42 Life Sciences GmbH & Co KG.
The Group (based in Berlin, Bremerhaven and Bargteheide) is a fully integrated developer, manufacturer, and distributor of in-situ hybridization (ISH) and immunohistochemistry (IHC) cancer diagnostics tests and equipment for clinical pathology labs in hospitals and private practices.
These diagnostic tools enable clinicians to understand the genetic changes that occur (or do not occur) in individual patients’ tumors. This approach, which is evolving quickly after recent technological and chemical advances, permits precision medical treatment, in which doctors create more effective, customized care based on a genetic understanding of how the disease is evolving in individual patients.
The Group has a direct presence in Germany and sells its products internationally via a distribution network. Zyto Group is the fourth largest provider of IHC products and the second largest provider of ISH products in Germany. The Group offers the broadest product portfolio and the highest service quality in the industry. The combined companies offer over 40,000 products, which cover IHC consumables (primary antibodies, detection systems and ancillary reagents), ISH consumables (probes, kits and reagents for both FISH and CISH, for manual use or semi-automated instruments) and automation instruments.